HIMA
This article was originally published in The Gray Sheet
Executive Summary
Mary Plock is named VP-public affairs at the Health Industry Manufacturers Association. Prior to joining HIMA, Plock focused on medical product issues as an executive at the public relations firm of Goddard Claussen Porter Novelli since 1998. She replaces Karen Alcorn, who left HIMA in August 1999 after nearly six years to join Hill & Knowlton as managing director ot its U.S. health practice. Separately, HIMA Director-Global Strategy and Analysis Paul Barry has been promoted to associate VP-global strategy and analysis
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.